AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32339253
Drug: Paclitaxel (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (80 mg/m2) plus everolimus (10 mg daily) in patients with prior taxane use
Trial: 33206309
Drug: Systemic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic therapy (ST) after RT (n = 999)
Trial: 33206309
Drug: Targeted therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted therapy after RT
Trial: 33206309
Drug: Hormone therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone therapy after RT
Trial: 33206309
Drug: Cytotoxic chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytotoxic chemotherapy after RT
Trial: 33206309
Drug: Immunotherapy after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy after RT
Trial: 33206309
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of ST after RT
Trial: 34387964
Drug: Paracetamol +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol + Ibuprofen (PCM + IBU)
Trial: 34387964
Drug: Paracetamol (PCM)
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paracetamol (PCM)
Trial: 34387964
Drug: Half Strength-Paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half Strength-Paracetamol + Ibuprofen (HS-PCM + IBU)
Trial: 34387964
Drug: Non-opioid analgesics
RxNorm normalized name: Non-opioid analgesics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-opioid analgesics before surgery
Trial: 34387964
Drug: No analgesics
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No analgesics before surgery
Trial: 36438254
Drug: Oral HIV
RxNorm normalized name: HIV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral HIV self-testing
Trial: 32643543
Drug: Group hypnosis
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group hypnosis sessions (5 weekly sessions plus audio recordings)
Trial: 33902621
Drug: RPH-104 80
RxNorm normalized name: RPH-104
DrugBank: Goflikicept (DB16396)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RPH-104 80 mg
Trial: 33902621
Drug: RPH-104 160
RxNorm normalized name: RPH-104
DrugBank: Goflikicept (DB16396)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RPH-104 160 mg
Trial: 34802107
Drug: Barbed reposition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Barbed reposition pharyngoplasty (BRP) surgery with preoperative drug-induced sleep endoscopy (DISE) evaluation (Group B)
Trial: 34802107
Drug: Barbed reposition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Barbed reposition pharyngoplasty (BRP) surgery without preoperative drug-induced sleep endoscopy (DISE) evaluation (Group A)
Trial: 34324016
Drug: Fluoroscopy-guided injection
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoroscopy-guided injection
Trial: 32914911
Drug: Non-image-guided injection
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-image-guided injection
Trial: 35302631
Drug: Treatment drugs
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment drugs
Trial: 33957337
Drug: Topical estradiol
RxNorm normalized name: estradiol Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical estradiol (2 mg)
Trial: 33957337
Drug: Belief of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Belief of receiving estradiol treatment
Trial: 34627809
Drug: 0.05% atropine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% atropine continued treatment
Trial: 34627809
Drug: 0.025% atropine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.025% atropine continued treatment
Trial: 34627809
Drug: 0.01% atropine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.01% atropine continued treatment
Trial: 34627809
Drug: Overall continued
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall continued treatment
Trial: 36401274
Drug: SVV-based goal-directed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SVV-based goal-directed fluid therapy (GDFT) with 3 ml/kg hydroxyethyl starch solution when SVV > 15% for more than 5 min intraoperatively
Trial: 32916308
Drug: Concurrent chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiotherapy (CRT) with pembrolizumab
Trial: 34328366
Drug: Early rhythm
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early rhythm control therapy (ERC; using antiarrhythmic drugs or catheter ablation)
Trial: 34328366
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (allowing rhythm control therapy to improve symptoms)
Trial: 34328366
Drug: Early rhythm
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early rhythm control therapy (ERC)
Trial: 32354780
Drug: Melatonin 4
RxNorm normalized name: vit B/folic acid/calcium/soy xt/black cohosh xt/melatonin 400 mcg-125 mg-62 mg-40 mg (day)/175 mg-62 mg-1 mg (night) ORAL CAPSULE, SEQUENTIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 4 mg
Trial: 36287306
Drug: Berdazimer gel,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Berdazimer gel, 10.3%, applied once daily for 12 weeks
Trial: 35246028
Drug: Aspirin group
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin group (n=11)
Trial: 35246028
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (Aspirin and DAPT)
Trial: 35770120
Drug: Norepinephrine therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine therapy (0.050.5 μg∗kg‐1/min)
Trial: 35770120
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (115 μg/kg∗min dopamine)
Trial: 35770120
Drug: Norepinephrine therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine therapy
Trial: 32795562
Drug: Dual-task training
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual-task training (20 sessions, 1 hour each, twice a week)
Trial: 32795562
Drug: Single-task training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-task training (20 sessions, 1 hour each, twice a week)
Trial: 34670042
Drug: 1200 mg
RxNorm normalized name: aspirin 1200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg lanifibranor
Trial: 34670042
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg lanifibranor
Trial: 35941584
Drug: Canagliflozin treatment
RxNorm normalized name: Canagliflozin
DrugBank: Canagliflozin (DB08907)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Canagliflozin treatment for 24 weeks
Trial: 35941584
Drug: Glimepiride treatment
RxNorm normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glimepiride treatment for 24 weeks
Trial: 33236103
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (DR-HC and TID-HC)
Trial: 32912140
Drug: Adherence to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adherence to WHO guidelines for antibiotic treatment
Trial: 32859392
Drug: Heparin-bonded polytetrafluoroethylene
RxNorm normalized name: polytetrafluoroethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-bonded polytetrafluoroethylene
Trial: 33783339
Drug: Training program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Training program for PEP prescription guidelines
Trial: 35927740
Drug: Customized adherence
RxNorm normalized name: sulfur
DrugBank: Octasulfur (DB09353)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Customized adherence enhancement (CAE) delivered via telehealth communications, comprising up to four standard treatment modules: Psychoeducation, Communication with Providers, Medication Routines, and Modified Motivational Interviewing.
Trial: 33010046
Drug: Pharmacokinetically guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacokinetically guided dosing of pazopanib
Trial: 34617261
Drug: Allopurinol 20
RxNorm normalized name: allopurinol 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol 20 mg/kg (first dose), 10 mg/kg (second dose if undergoing therapeutic hypothermia)
Trial: 39773886
Drug: Aspirin-clopidogrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin-clopidogrel
Trial: 34304604
Drug: Aspirin-dipyridamole
RxNorm normalized name: aspirin-dipyridamole
DrugBank: Dipyridamole (DB00975)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin-dipyridamole
Trial: 32645078
Drug: Belief that
RxNorm normalized name: Ora Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Belief that HBV vaccine was safe
Trial: 32127214
Drug: Extracorporeal Shock
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal Shock Wave Therapy
Trial: 36255730
Drug: Gram stain-guided
RxNorm normalized name: fluorexon stain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gram stain-guided initial antibiotic therapy
Trial: 34107720
Drug: Combined supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined supplementation with vitamin D (40,000 IU) and omega-3 fatty acids (8,000 mg) twice a day for 6 weeks
Trial: 32229541
Drug: Pulmonary tele-rehabilitation
RxNorm normalized name: Lobaria pulmonaria extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulmonary tele-rehabilitation (PTR) for 10 weeks (60 min, three times weekly)
Trial: 32229541
Drug: Conventional pulmonary
RxNorm normalized name: Lobaria pulmonaria extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional pulmonary rehabilitation (PR) for 10 weeks (90 min, two times weekly)
Trial: 33369253
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment (C)
Trial: 32955455
Drug: Mobile health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile health (mHealth): entertaining educational audio capsules and voice immunization reminders via mobile phone
Trial: 36066319
Drug: Restrictive transfusion
RxNorm normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive transfusion strategy (RBCs transfused when hemoglobin <7.5 g/dl)
Trial: 36066319
Drug: Liberal transfusion
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liberal transfusion strategy (transfusion triggers: <9.5 g/L intraoperatively, <9.5 g/L in intensive care, <8.5 g/dl on the ward)
Trial: 34418670
Drug: NMES +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NMES + exercise therapy
Trial: 33402575
Drug: Topical Betamethasone
RxNorm normalized name: betamethasone Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Betamethasone Valerate 0.1% cream, applied twice daily during radiotherapy/chemo-radiotherapy
Trial: 35089205
Drug: Antibiotic cement
RxNorm normalized name: Cement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic cement coating group
Trial: 33832490
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of periodontal curettage and root planing
Trial: 35385050
Drug: Canakinumab (50,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canakinumab (50, 150, and 300 mg once every 3 months)
Trial: 35954937
Drug: Seawater hydration
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seawater hydration (Totum SPORT, Laboratories Quinton International, S.L., Valencia, Spain)
Trial: 33533155
Drug: 2.5% agarose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5% agarose gel
Trial: 33533155
Drug: NASHA-L
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NASHA-L
Trial: 33533155
Drug: 2.5% agarose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5% agarose gel and NASHA-L
Trial: 32853585
Drug: Ipilimumab group
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab group (brentuximab vedotin 1.8 mg/kg with ipilimumab 1 mg/kg or 3 mg/kg)
Trial: 32853585
Drug: Nivolumab group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab group (brentuximab vedotin 1.2 mg/kg or 1.8 mg/kg with nivolumab 3 mg/kg)
Trial: 32853585
Drug: Triplet therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triplet therapy group (brentuximab vedotin 1.2 mg/kg or 1.8 mg/kg with nivolumab 3 mg/kg and ipilimumab 1 mg/kg)
Trial: 34112001
Drug: Taurolock‐hep500™ as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taurolock‐hep500™ as a catheter lock solution
Trial: 34112001
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin as a catheter lock solution
Trial: 34656191
Drug: SET‐C (Social
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SET‐C (Social Effectiveness Therapy for Children)
Trial: 32256897
Drug: Medication review
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication review service (delivered by clinical pharmacists)
Trial: 32256897
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no medication review service)
Trial: 34289820
Drug: Extensively hydrolyzed
RxNorm normalized name: collagen, hydrolyzed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extensively hydrolyzed formula (EHF) at 2.4 g protein/100 kcal
Trial: 34289820
Drug: Amino acid-based
RxNorm normalized name: silk amino acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid-based formula (AAF) at 2.4 g total protein equivalents/100 kcal
Trial: 34289820
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (EH casein formula at 2.8 g protein/100 kcal)
Trial: 34528408
Drug: Repository corticotropin
RxNorm normalized name: Repository Corticotropin Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repository corticotropin injection (RCI; 80 IU subcutaneously twice weekly on study days 1 and 4)
Trial: 34528408
Drug: Synthetic ACTH1-24
RxNorm normalized name: Camphor (synthetic)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic ACTH1-24 depot (1 mg subcutaneously twice weekly on study days 1 and 4)
Trial: 34528408
Drug: Methylprednisolone (32
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (32 mg orally once daily on study days 1 through 6)
Trial: 35186225
Drug: Routine nursing
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Routine nursing during chemotherapy (CG)
Trial: 33507984
Drug: Annual caries
RxNorm normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Annual caries preventive intervention including placement of fissure sealants, application of povidone-iodine and fluoride varnish, and standard diet and oral hygiene advice.
Trial: 33139757
Drug: Probiotic supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic supplementation (Bifidobacterium-animalis-subsp.-Lactis 10×10^9 and Lactobacillus-Acidophilus 10×10^9 + 5 g of maltodextrin)
Trial: 32649856
Drug: GRK5 variant
RxNorm normalized name: Valiant Barrier
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GRK5 variant (rs10886430-G)
Trial: 32649856
Drug: G protein-coupled
RxNorm normalized name: G 1 (g protein-coupled estrogen receptor agonist)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G protein-coupled receptor kinase 5 (GRK5)
Trial: 35427476
Drug: DC371739 +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DC371739 + Atorvastatin
Trial: 32709507
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of 4 drops of 2% lavender essential oil with oxygen for 20 minutes
Trial: 32709507
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of oxygen only
Trial: 33067319
Drug: Axitinib (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Axitinib (5 mg oral two times per day) plus avelumab (10 mg/kg intravenous every 2 weeks) in Cohort-1
Trial: 33067319
Drug: Axitinib monotherapy
RxNorm normalized name: Axitinib
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Axitinib monotherapy in Cohort-2 (avelumab added after 6 weeks if corticosteroid dose could be tapered to ≤8 mg)
Trial: 35394525
Drug: Positive STEPS
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Positive STEPS intervention (community health worker-led, 7-week duration, weekly telephone sessions, web-based videos, positive activities, wearable activity trackers)
Trial: 33760027
Drug: edoxaban (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: edoxaban (oral factor Xa inhibitor)
Trial: 32792320
Drug: L-thyroxine (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-thyroxine (n = 40)
Trial: 32311555
Drug: Low-Molecular-Weight Heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-Molecular-Weight Heparin (LMWH) for 14 days in patients older than 70 years
Trial: 32311555
Drug: Low-Molecular-Weight Heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-Molecular-Weight Heparin (LMWH) in patients younger than 70 years
Trial: 35961517
Drug: High-dose autologous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose autologous skeletal muscle-derived cells
Trial: 35961517
Drug: Low-dose autologous
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose autologous skeletal muscle-derived cells
Trial: 35545584
Drug: Standard triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard triple therapy for 10 days
Trial: 32171637
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acids intervention (specific dosage and duration not mentioned)
Trial: 35261299
Drug: Desogestrel (DSG)
RxNorm normalized name: Desogestrel
DrugBank: Desogestrel (DB00304)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desogestrel (DSG) 0.075 mg
Trial: 34269455
Drug: 450-ml blood
RxNorm normalized name: SUS SCROFA BLOOD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 450-ml blood donation
Trial: 36418502
Drug: Experimental desensitizing
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Experimental desensitizing gel (10% calcium gluconate, 0.1% dexamethasone acetate, 10% potassium nitrate, 5% glutaraldehyde) applied for 10 min before bleaching.
Trial: 36418502
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel applied for 10 min before bleaching.
Trial: 32347977
Drug: Oral melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral melatonin 3 mg/d (immediate-release) at bedtime
Trial: 35614395
Drug: Liberal Fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liberal Fluid Infusion (LFI)
Trial: 36180962
Drug: Blended therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blended therapy with therapeutic online intervention (TONI) containing 12 transdiagnostic online modules
Trial: 35114141
Drug: Concomitant administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concomitant administration of QIV-HD and mRNA-1273 vaccine
Trial: 35114141
Drug: mRNA-1273 vaccine
RxNorm normalized name: SARS-CoV-2 mRNA-1273 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-1273 vaccine alone
Trial: 32228743
Drug: Control diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control diet with 0.5 g/day of SDR (SDR0.5)
Trial: 32228743
Drug: Control diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control diet with 1 g/day of SDR (SDR1)
Trial: 32228743
Drug: Control diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control diet with 1.5 g/day of SDR (SDR1.5)
Trial: 35652829
Drug: Beetroot juice
RxNorm normalized name: tamarind juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beetroot juice (BRJ) ingestion (140 mL, ∼12.8 mmol of nitrate)